Streetbeat News

Equity Actions

CL

Colgate-Palmolive has updated its FY23 outlook, expecting net sales growth of 5% to 8%, including the benefit from acquisitions of pet food businesses and a low-single-digit negative impact from foreign exchange. The company also expects organic sales growth of 5% to 7%. On a GAAP basis, it expects gross profit margin expansion, increased advertising investment, and double-digit earnings-per-share growth. On a non-GAAP basis, it expects earnings-per-share growth to be at the high end of mid-single-digits.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 10:59 am

NVT

NVent Electric Plc (NYSE:NVT) has revised its FY23 guidance, now expecting an adjusted EPS of $2.85-$2.91, up from the previous guidance of $2.65-$2.73. The company also anticipates a reported sales growth of 13%-15%, a significant increase from the prior guidance of 4% to 6%.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 10:41 am

AULT

Ault Alliance has contracted Shareholder Intelligence Services, LLC to investigate potential illegal short selling activities in its common stock.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 10:33 am

ZIVO

Zivo Bioscience has filed a prospectus for 2,996,260 shares of common stock underlying Series A and Series B common warrants by a selling stockholder. The filing was made with the SEC.

Portfolio Pulse from Charles Gross

July 28, 2023 | 10:08 am

CLS

RBC Capital analyst Maxim Matushansky has upgraded Celestica (NYSE:CLS) from Sector Perform to Outperform and raised the price target from $14 to $22.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:23 am

NYCB

JP Morgan analyst Steven Alexopoulos has upgraded New York Community (NYSE:NYCB) from Neutral to Overweight and raised the price target from $13 to $16.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:19 am

TM

Toyota Motor Corporation (TM) plans to sell 20% of its stake in KDDI, a deal worth approximately $1.8 billion. The move is part of Toyota's strategy to streamline its assets and focus on its core business.

Portfolio Pulse from Charles Gross

July 28, 2023 | 9:07 am

SNY

Sanofi has revised its full-year 2023 business EPS guidance upward, now expecting it to grow by mid-single-digit at CER, barring unforeseen major adverse events. This includes an estimated €400 million of expected one-off COVID vaccine revenues in the second half of the year. However, the currency impact on 2023 business EPS is estimated between -6.5% to -7.5%.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 7:08 am

INZY

Inozyme Pharma has priced its public offering of 12.5 million common stocks at $4.80 per share.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 6:28 am

TNXP

Tonix Pharmaceuticals has priced its public offering of 7 million common shares at $1 per share. The closing of the public offering is expected to occur on or about August 1, 2023.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 6:15 am